382 related articles for article (PubMed ID: 1671029)
1. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study.
Hadengue A; Moreau R; Bacq Y; Gaudin C; Braillon A; Lebrec D
Hepatology; 1991 Jan; 13(1):111-6. PubMed ID: 1671029
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
3. Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis.
Bacq Y; Gaudin C; Hadengue A; Roulot D; Braillon A; Moreau R; Lebrec D
Hepatology; 1991 Sep; 14(3):483-7. PubMed ID: 1874493
[TBL] [Abstract][Full Text] [Related]
4. Intrarenally produced angiotensin II opposes the natriuretic action of the dopamine-1 receptor agonist fenoldopam in rats.
Chen CJ; Apparsundaram S; Lokhandwala MF
J Pharmacol Exp Ther; 1991 Feb; 256(2):486-91. PubMed ID: 1671595
[TBL] [Abstract][Full Text] [Related]
5. Effects of dopamine DA1-receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anaesthetized dog.
Clark KL; Hilditch A; Robertson MJ; Drew GM
J Hypertens; 1991 Dec; 9(12):1143-50. PubMed ID: 1685741
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects.
Bughi S; Horton R; Antonipillai I; Manoogian C; Ehrlich L; Nadler J
J Clin Endocrinol Metab; 1989 Dec; 69(6):1116-21. PubMed ID: 2573613
[TBL] [Abstract][Full Text] [Related]
7. The effect of fenoldopam on renal haemodynamics and natriuresis in chronic renal failure.
de Fijter CW; Comans EF; de Vries PM; Oe PL; Roos JC; Smit AJ; Streurman O; Donker AJ
Neth J Med; 1990 Jun; 36(5-6):267-78. PubMed ID: 1975651
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and renal hemodynamic effects of A-68930 in the conscious dog: a comparison with fenoldopam.
Christie MI; Smith GW
J Pharmacol Exp Ther; 1994 Feb; 268(2):565-70. PubMed ID: 7906731
[TBL] [Abstract][Full Text] [Related]
9. Evidence from functional and autoradiographic studies for the presence of tubular dopamine-1 receptors and their involvement in the renal effects of fenoldopam.
Hedge SS; Ricci A; Amenta F; Lokhandwala MF
J Pharmacol Exp Ther; 1989 Dec; 251(3):1237-45. PubMed ID: 2574743
[TBL] [Abstract][Full Text] [Related]
10. Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog.
Nichols AJ; Koster PF; Brooks DP; Ruffolo RR
J Pharmacol Exp Ther; 1992 Jan; 260(1):269-74. PubMed ID: 1346161
[TBL] [Abstract][Full Text] [Related]
11. Ontogeny of renal response to specific dopamine DA1-receptor stimulation in sheep.
Segar JL; Smith FG; Guillery EN; Jose PA; Robillard JE
Am J Physiol; 1992 Oct; 263(4 Pt 2):R868-73. PubMed ID: 1357989
[TBL] [Abstract][Full Text] [Related]
12. SK&F 87516, a close analog of fenoldopam, is a partial agonist at dopamine-1 and alpha-2 receptors and produces stimulation of 5-hydroxytryptamine-2 receptors in the cardiovascular system of the rat.
Le Monnier de Gouville AC; Lawson K; Thiry C; Cavero I
J Pharmacol Exp Ther; 1991 Mar; 256(3):1049-56. PubMed ID: 1672375
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of a specific dopaminergic receptor agonist with metoclopramide in horses.
Eades SC; Moore JN
Am J Vet Res; 1993 Jan; 54(1):122-5. PubMed ID: 8093992
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis.
La Villa G; Lazzeri C; Pascale A; Sestini S; Bisi G; Sciagrà R; Vecchiarino S; Raggi VC; Barletta G; Laffi G; Gentilini P
Am J Gastroenterol; 1997 May; 92(5):852-7. PubMed ID: 9149200
[TBL] [Abstract][Full Text] [Related]
15. Systemic and pulmonary vascular effects of selective dopamine receptor blockade and stimulation in lambs.
Polak MJ; Drummond WH
Pediatr Res; 1993 Feb; 33(2):181-4. PubMed ID: 8094550
[TBL] [Abstract][Full Text] [Related]
16. Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells.
Grenader A; Healy DP
J Pharmacol Exp Ther; 1991 Jul; 258(1):193-8. PubMed ID: 1677038
[TBL] [Abstract][Full Text] [Related]
17. Selective peripheral dopamine-1 receptor stimulation. Differential responses to sodium loading and depletion in humans.
Ragsdale NV; Lynd M; Chevalier RL; Felder RA; Peach MJ; Carey RM
Hypertension; 1990 Jun; 15(6 Pt 2):914-21. PubMed ID: 1972140
[TBL] [Abstract][Full Text] [Related]
18. Human vasodilator responses to a dopamine agonist: possible mechanisms.
Redman D; Thom SA; Hughes AD; Hasan S; Sever PS
J Hypertens Suppl; 1985 Dec; 3(3):S177-8. PubMed ID: 2908815
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the effects of dopamine-1 and dopamine-2 receptor agonists on coronary flow.
Zhao RR; Wang PH; Zhang WF; Fennell WH
Methods Find Exp Clin Pharmacol; 1992; 14(1):5-11. PubMed ID: 1352371
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of lithium on the renal response to DA1-dopamine receptor stimulation by fenoldopam in normal man.
Girbes AR; Smit AJ; Meijer S; Reitsma WD
Br J Clin Pharmacol; 1990 Apr; 29(4):413-5. PubMed ID: 1970264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
